Are We Ready for Biosimilars in Gastroenterology?
Biologics are large complex molecules that are produced in living systems. They have revolutionised the treatment of patients suffering from various diseases, including inflammatory bowel disease. However, in many parts of the world, patient access to biologics has been hampered, mainly because of t...
Main Authors: | Muhammad Ilham Abdul Hafidz, Thevaraajan Jayaraman, Raja Affendi Raja Ali, Yeong Yeh Lee |
---|---|
Format: | Article |
Language: | English |
Published: |
European Medical Journal
2017-12-01
|
Series: | European Medical Journal Gastroenterology |
Subjects: | |
Online Access: | https://www.emjreviews.com/gastroenterology/article/are-we-ready-for-biosimilars-in-gastroenterology/ |
Similar Items
-
Biosimilars: concept, current status, and future perspectives in inflammatory bowel diseases
by: Sang Hyoung Park, et al.
Published: (2020-01-01) -
Loss of response and frequency of adverse events in patients with ulcerative colitis and Crohn’s disease when switching from the original infliximab to its biosimilars
by: O. V. Knyazev, et al.
Published: (2021-02-01) -
Biosimilar biological drugs in the treatment of inflammatory bowel diseases
by: Magdalena Kaniewska, et al.
Published: (2019-12-01) -
Inflammatory bowel disease in Bahrain: single-center experience
by: Abdulla M, et al.
Published: (2017-07-01) -
The Role of Biologics Agent in the Treatment of Inflammatory Bowel Disease
by: Tri Hapsoro Guno, et al.
Published: (2017-12-01)